A Lièvre1, P Artru2, M Guiu3, P Laurent-Puig4, J L Merlin5, J C Sabourin6, J Viguier7, A Bastie8, A Seronde8, M Ducreux9. 1. Medical Oncology Department, René Huguenin Hospital, Institut Curie, 35 Rue Dailly, 92210 Saint-Cloud, France; University of Versailles Saint-Quentin en Yvelines, Faculty of Health Sciences, 45 Avenue des États Unis, 78000 Versailles, France. Electronic address: astrid.lievre@curie.net. 2. Hepato-Gastro-Enterology and Digestive Oncology Department, Hopital Jean Mermoz, 55 Avenue Jean Mermoz, 69008 Lyon, France. 3. Anatomy-Pathology Office, 2 Avenue des Palmiers, 66006 Perpignan, France. 4. Biochemistry Department, Hopital Européen Georges Pompidou, 20 Rue Leblanc, 75015 Paris, France; University of Paris Descartes, Faculty of Health Sciences, 12 Rue de l'École de Médecine, 75006 Paris, France. 5. Biopathology Department, Centre Alexis Vautrin, 6 Avenue de Bourgogne, 54519 Nancy, France; University of Lorraine, 4 Rue de la Ravinelle, 54000 Nancy, France; CNRS UMR 7039, CRAN, Boulevard des Aiguillettes, 54506 Vandœuvre-lès-Nancy, France. 6. Anatomy and Pathological Cytology Department, CHU Charles Nicolle, 1 Rue de Germont, 76000 Rouen, France. 7. Hepato-Gastro-Enterology and Digestive Oncology Department, Hopital Trousseau, Avenue de la République, 37170 Chambray-lès-Tours, France. 8. Oncology Unit, Merck-Serono, 37 Rue Saint-Romain, 69008 Lyon, France. 9. Gastro-Enterology Unit, Institut Gustave Roussy, 114 Rue Édouard Vaillant, 94800 Villejuif, France; Paris Sud University, 63 Rue Gabriel Péri, 94270 Le Kremlin Bicetre, France.
Abstract
BACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-epidermal growth factor receptor (EGFR) antibody in the treatment of metastatic colorectal carcinoma (mCRC). PATIENTS AND METHODS: This observational retrospective study was performed in 160 French centres during a 2-week period in 2011. Its main objective was to evaluate the rate of KRAS testing in patients with mCRC having initiated their first-line therapy. Secondary objectives included time of process, techniques used and reasons for non-prescription. RESULTS: Five hundred and thirty eight mCRC patients (67.1 ± 11.3 years, synchronous metastases: 69.9%) were enrolled in the study. KRAS testing was prescribed in 81.1% of patients, in a median of 15 days after the diagnosis of metastases, and of 15 days prior to the initiation of the first-line metastatic chemotherapy. KRAS status was available for 87% of patients, after 23.6 ± 28.2 days, but after the choice of the first-line therapy in 56.6% of patients. Heterogeneity of reception time was noteworthy within regions (8.3 ± 7 days to 38.8 ± 101 days). KRAS testing was not prescribed mainly due to the planned non-prescription of an anti-EGFR antibody. CONCLUSION: This study confirmed that KRAS testing is definitely part of the management of most of mCRC patients, despite discrepancies observed in the rate of prescription and the time of results.
BACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-epidermal growth factor receptor (EGFR) antibody in the treatment of metastatic colorectal carcinoma (mCRC). PATIENTS AND METHODS: This observational retrospective study was performed in 160 French centres during a 2-week period in 2011. Its main objective was to evaluate the rate of KRAS testing in patients with mCRC having initiated their first-line therapy. Secondary objectives included time of process, techniques used and reasons for non-prescription. RESULTS: Five hundred and thirty eight mCRC patients (67.1 ± 11.3 years, synchronous metastases: 69.9%) were enrolled in the study. KRAS testing was prescribed in 81.1% of patients, in a median of 15 days after the diagnosis of metastases, and of 15 days prior to the initiation of the first-line metastatic chemotherapy. KRAS status was available for 87% of patients, after 23.6 ± 28.2 days, but after the choice of the first-line therapy in 56.6% of patients. Heterogeneity of reception time was noteworthy within regions (8.3 ± 7 days to 38.8 ± 101 days). KRAS testing was not prescribed mainly due to the planned non-prescription of an anti-EGFR antibody. CONCLUSION: This study confirmed that KRAS testing is definitely part of the management of most of mCRC patients, despite discrepancies observed in the rate of prescription and the time of results.
Authors: Gebra Cuyun Carter; Pamela B Landsman-Blumberg; Barbara H Johnson; Paul Juneau; Steven J Nicol; Li Li; Veena Shankaran Journal: J Exp Clin Cancer Res Date: 2015-03-27
Authors: Carlo Barone; Carmine Pinto; Nicola Normanno; Lorenzo Capussotti; Francesco Cognetti; Alfredo Falcone; Lorenzo Mantovani Journal: PLoS One Date: 2014-01-20 Impact factor: 3.240
Authors: J Han J M Van Krieken; Etienne Rouleau; Marjolijn J L Ligtenberg; Nicola Normanno; Scott D Patterson; Andreas Jung Journal: Virchows Arch Date: 2015-11-16 Impact factor: 4.064
Authors: Allan Wee Ren Ng; Pei Jun Tan; Winfrey Pui Yee Hoo; Lionel Lian Aun In; Dek Shen Liew; Michelle Yee Mun Teo; Pui Yan Siak; Sze Man Ng; Ee Wern Tan; Raha Abdul Rahim; Renee Lay Hong Lim; Adelene Ai Lian Song Journal: PeerJ Date: 2018-07-20 Impact factor: 2.984